ctDNA blood tests to guide treatment in colorectal cancer with liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study prospectively collects blood samples to evaluate the performance of circulating tumor DNA diagnostics in colorectal cancer with liver metastases. It aims to benchmark available ctDNA tests at key clinical points such as after surgery, after adjuvant therapy, during chemotherapy, and during follow-up. By comparing ctDNA results with clinical outcomes, the study seeks to identify which tests best inform decisions about multi-modal therapy and surveillance. The work is part of the GUIDE.MRD consortium and focuses on defining clinical utility and standardizing ctDNA testing. Recruitment is conducted at CHU de Montpellier in France under the lead sponsor, University Hospital Montpellier.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient 18 years or older.
* Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT.
* Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor.
* Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)

Exclusion Criteria:

* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.
* Extrahepatic metastases
* Malignant colorectal polyps diagnosed after polypectomy.
* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)
* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening
* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.
* Liver cirrhosis
* CRLM intervention/surgery cannot be/was not performed with curative intent
* No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor)
* Pregnant or nursing woman, or in childbearing age and not willing to use contraception
* Protected and vulnerable adult
* Not covered by Health insurance
* Patient unable to understand and sign written informed consent.

Where it's running

• CHU de Montpellier
  Montpellier, France Recruiting
• Institu régional du Cancer de Montpellier (ICM)
  Montpellier, France Recruiting

Study contacts

• Principal investigator: Thomas BARDOL, M.D. — University Hospital, Montpellier
• Study coordinator: Catherine ALIX-PANABIERES, Ph.D.
• Email: c-panabieres@chu-montpellier.fr
• Phone: +33411759931

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• French testing of blood-based ctDNA to find leftover cancer after surgery in Stage III colorectal cancer

  We will test whether blood-based ctDNA can find leftover cancer after surgery in people with Stage III colorectal cancer to help guide additional treatment.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287814

• French test of leftover tumor DNA in the blood after pancreatic cancer surgery

  This will test whether a blood test for tumor DNA after surgery or after adjuvant chemotherapy can find pancreatic cancer patients at high risk of relapse.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287749

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.